Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00291525 · ClinicalTrials.gov registry record · NA
Randomized On-X Anticoagulation Trial
A NA study, sponsored by On-X Life Technologies.
- Completed
- Registry status
- NA
- Development phase
- 977
- Enrollment target
NCT00291525: Completed NA study, sponsored by On-X Life Technologies.
NCT00291525 is a NA study that has completed, run by On-X Life Technologies. The registered enrollment target is 977 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (30% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00291525, a NA study, has completed, sponsored by On-X Life Technologies.
- COMPLETED
- Registry status
- NA
- Development phase
- 977 participants
- Enrollment target
Study Summary
Various patient groups with the On-X Valve can be maintained safely on lower doses of blood thinner(Coumadin®) or on antiplatelet drugs (aspirin/Plavix®) only rather than the standard dose of Coumadin and aspirin presently recommended by ACC/AHA or ACCP professional societies.
Primary Outcome
Percentage of events per patient year
Interventions
- DEVICE On-X valve using reduced anticoagulation
- DEVICE On-X Valve with Standard warfarin Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 977 participants |
| Start Date | 2006-06-06 |
| Est. Completion | 2023-12-29 |
| Phase | NA |
What the finished NCT00291525 record still lists
NCT00291525 is an interventional study that assigns participants to a tested intervention. The registered 977 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (30% lower).
The record links to 0 conditions, and to 2 interventions - of which On-X valve using reduced anticoagulation is the first listed.
NCT00291525 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00291525 about?
NCT00291525 is a clinical study titled "Randomized On-X Anticoagulation Trial". Various patient groups with the On-X Valve can be maintained safely on lower doses of blood thinner(Coumadin®) or on antiplatelet drugs (aspirin/Plavix®) only rather than the standard dose of Coumadin and aspirin presently recommended by ACC/AHA or ACCP professional societies.
What is the current status of trial NCT00291525?
This trial is currently completed. It is a NA study. The enrollment target is 977 participants. The study started on 2006-06-06. Estimated completion is 2023-12-29.
What interventions are being tested in trial NCT00291525?
The interventions under investigation include: On-X valve using reduced anticoagulation (DEVICE), On-X Valve with Standard warfarin Therapy (DEVICE).
Who is sponsoring clinical trial NCT00291525?
This trial is sponsored by On-X Life Technologies, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00291525's enrollment target sits among peer trials
977 122nd of 2000 higher than 1,879 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06988306 · 978 participants · NA
Lifestyle Interventions to Prevent Diabetes in U.S. Home Visiting Programs
- NCT05600777 · 975 participants · Phase 3
A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
- NCT06541704 · 975 participants · Phase 3
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
- NCT06820736 · 975 participants · NA
A Prospective, Randomized Comparison Of Drainage Techniques After One- Or Two-Level Open Posterior Lumbar Decompression Or Decompression And Fusion
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI